Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has announced the issuance and conversion of unquoted equity securities, with a total of 187,668 ordinary fully paid securities being issued. This move may impact the company’s financial structure and could have implications for its market positioning and shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company is involved in medical testing and diagnostics, serving a wide range of healthcare providers and patients across Australia.
Average Trading Volume: 1,058,077
Technical Sentiment Signal: Sell
Current Market Cap: A$524.7M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.